
IRadimed Corp IRMD.OQ IRMD.O is expected to show a rise in quarterly revenue when it reports results on August 1 for the period ending June 30 2025
The Winter Springs Florida-based company is expected to report a 11.6% increase in revenue to $20.006 million from $17.93 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on May 5 2025, for the period ended June 30, was for revenue between $19.70 million and $19.90 million.
LSEG's mean analyst estimate for IRadimed Corp is for earnings of 44 cents per share. The company's EPS guidance on May 5 2025, for the period ended June 30, was between $0.41 and $0.44
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for IRadimed Corp is $71.00, about 20.7% above its last closing price of $56.32
This summary was machine generated July 28 at 11:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)